山东科源制药股份有限公司 章 程 2025 年 12 月 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 2 | | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 3 | | | 第三节 | 股份转让 | 4 | | 第四章 | 股东和股东会 5 | | | 第一节 | 股东的一般规定 5 | | | 第二节 | 控股股东和实际控制人 8 | | | 第三节 | 股东会的一般规定 9 | | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 14 | | | 第六节 | 股东会的召开 | 16 | | 第七节 | 股东会的表决和决议 19 | | | 第五章 | 董事会 | 24 | | 第一节 | 董事的一般规定 24 | | | 第二节 | 董事会 | 27 | | 第三节 | 独立董事 | 33 | | 第四节 | 董事会专门委员会 35 | | | 第六章 | 高级管理人员 | 37 | | 第七章 | 财务会计制度、利润分配和审计 39 | | | 第一节 ...

董事会议事规则 2025 年 12 月 山东科源制药股份有限公司 | | | 山东科源制药股份有限公司 董事会议事规则 山东科源制药股份有限公司 董事会议事规则 第一章 总则 第一条 为规范山东科源制药股份有限公司（以下简称"公司"）董事会 的议事方式和决策程序，促使董事和董事会有效地履行职责，提高董事会规范运 作和科学决策水平，充分发挥董事会的经营决策中心作用，根据《中华人民共和 国公司法》（以下简称《公司法》）、《山东科源制药股份有限公司章程》（以 下简称"公司章程"）、中国证券监督管理委员会（以下简称"中国证监会"） 和证券交易所的有关规定制定本议事规则。 第二条 董事会是公司的经营决策机构。董事会受股东会的委托，负责经 营和管理公司的法人财产，对股东会负责。 第三条 董事会由 7 名董事组成，其中 3 名为独立董事、1 名职工董事。 董事会设董事长 1 人，副董事长 1 人。董事长和副董事长由董事会以全体董事过 半数选举产生。独立董事中至少有一名会计专业人士。以会计专业人士身份被提 名为独立董事候选人的，应具备较丰富的会计专业知识和经验，并至少符合下列 条件之一： （一）具有注册会计师执业资格； 第四 ...

Group 1 - In December, several leading pharmaceutical companies experienced significant executive changes, including Guoyao Holdings, BeiGene, and Zhendong Pharmaceutical [1][2] - Kexin Pharmaceutical announced the election of Li Hongfu as the chairman of its fourth board of directors on December 1 [1] - Kang En Bei reported that Jiang Yi resigned from multiple positions, including chairman, on December 6 due to work adjustments [1] Group 2 - WuXi AppTec appointed Tian Feng as the CEO and executive director, effective December 29, 2025 [2] - Alibaba Health announced the resignation of Zhu Shunyan as non-executive director and chairman, with current CEO Shen Difan taking over as chairman [2] - Sangfor Technologies reported the resignation of core technical personnel, Weng Zhibing, from all positions in its wholly-owned subsidiary on December 16 [2] Group 3 - Zhendong Pharmaceutical announced that Yang Lianmin resigned from his positions due to reaching retirement age on December 18 [2] - BeiGene appointed Dr. Wang Lai as president and global head of R&D, effective December 19 [2] - Guoyao Holdings announced Jin Bin as the new chairman on December 19, following the resignation of Zhao Bingxiang [2] Group 4 - Shijiazhuang Pharmaceutical Group reported that Zhang Cuilong stepped down from multiple roles, while Cai Lei was appointed as vice chairman and CEO on December 19 [3] - Weichuang Bio announced the appointment of Li Jianxun as general manager, while Chairman Lu Xianping stepped down from the general manager role on December 23 [3] - Shandong Pharmaceutical Glass reported that Chairman Hu Yonggang resigned from all positions due to age, with General Manager Zhang Jun taking over the chairman's responsibilities on December 24 [3]

证券日报网讯12月10日，科源制药（301281）在互动平台回答投资者提问时表示，公司股价波动受宏观 环境、市场情绪变化等多种因素影响，公司重视和关注股价，未来将继续专注主营业务，全力做好各项 经营管理工作，争取更好的业绩回报广大投资者。 ...

科源制药（301281.SZ）12月10日在投资者互动平台表示，尊敬的投资者您好，公司在海南投资设有子 公司海南林恒药业有限公司，主要业务为医药商业代理及配送服务，是公司在下游产业链的延伸。感谢 您的关注。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵司在海南省是否有子公司？是否在海南省有相 关业务布局？ ...

Group 1 - The company focuses on the chronic disease sector, specifically in the areas of three highs (hypertension, hyperglycemia, and hyperlipidemia) and cardiovascular raw materials [1] - The main raw materials for diabetes treatment include Glimepiride and Metformin Hydrochloride, while the primary cardiovascular raw material is Isosorbide Mononitrate [1] - Currently, the company has not ventured into the health supplement raw materials market [1]

本报（chinatimes.net.cn）记者于娜 北京报道 近日，创业板上市公司科源制药的一则公告，让持续一年多的"力诺系"内部资产整合大戏戛然而止。 据科源制药公告，公司终止收购山东宏济堂制药集团99.42%股权的重大资产重组事项，这意味着济南 前首富高元坤主导的，将百年老字号宏济堂曲线注入上市公司的资本运作正式搁浅。 科源制药与宏济堂同属济南前首富高元坤掌控的力诺集团，此次交易自2024年10月筹划以来，历经深交 所问询、反垄断审查通过等多重环节，一度被市场视为"力诺系"医药资产证券化的关键一步。 然而，在市场环境变化与企业自身业绩承压的双重作用下，这场涉及35.81亿元的关联交易最终折戟， 不仅让宏济堂的上市梦再次破碎，也暴露了"力诺系"资产腾挪背后的深层困境。 一场早有预兆的"资本局" 时间回溯至2024年10月8日，科源制药因筹划重大事项临时停牌，首次披露拟收购宏济堂股权的消息， 随即引发资本市场广泛关注。 作为交易核心标的，宏济堂的"百年字号"光环成为最大看点——这家创立于1907年的企业，创始人乐镜 宇是同仁堂第十二代传人、《大宅门》主人公白景琦的原型，1915年其阿胶产品曾斩获巴拿马万国博览 ...

Core Viewpoint - Koyuan Pharmaceutical announced the termination of its major asset restructuring plan to acquire 99.42% of Shandong Hongjitang's shares, citing changes in the overall market environment as the reason for this decision, which has led to a negative market reaction with stock price declines [1][6] Group 1: Financial Pressure - Koyuan Pharmaceutical has experienced a continuous decline in net profit since its listing in 2023, with a 3% year-on-year decrease in the first three quarters of 2023, a significant 41% drop in the same period of 2024, and a further 21% decline projected for the first three quarters of 2025 [2][7] - The proposed acquisition of Hongjitang for 3.581 billion yuan, with an estimated premium of 60.54%, posed a risk of significant earnings dilution for Koyuan, exacerbating its financial burden [2][7] - Hongjitang, despite its brand value exceeding 16 billion yuan, only committed to revenue targets without guarantees on profit, creating an asymmetric risk profile that could lead to a "merger drag" scenario for Koyuan [2][7] Group 2: Related Transactions - The acquisition was essentially an internal asset restructuring within the "Linuo System," with both Koyuan and Hongjitang controlled by the same individual, raising concerns about potential conflicts of interest due to the involvement of 38 related parties [3][8] - The transaction structure involved a share issuance priced at 16.7 yuan per share and a plan to raise up to 700 million yuan in supporting funds, which, combined with the high valuation and related party participation, led to market skepticism regarding potential benefit transfers [3][8] - The lack of profit guarantees in the agreement, while not violating regulations, tilted risk distribution towards the seller, undermining the credibility and fairness of the transaction [3][8] Group 3: Industry Changes - The pharmaceutical industry is undergoing significant structural adjustments, with normalized bulk purchasing and stricter regulatory policies impacting valuation logic, particularly for traditional Chinese medicine companies [4][9] - Hongjitang's key products face pressures from centralized procurement and price declines, challenging the rationale for high-premium acquisitions [4][10] - The market's cautious stance towards pharmaceutical mergers, especially cross-industry ones, has been reinforced by previous underwhelming integration outcomes, leading to decreased trust in such collaborative narratives [4][10] - Koyuan's decision to terminate the acquisition, while causing short-term stock volatility, may ultimately provide a necessary respite to refocus on its core business of chemical raw materials and maintain stable operations [4][10]

北京商报讯（记者 丁宁）12月4日晚间，科源制药（301281）发布公告称，公司于近日收到公司副总经 理、董事会秘书、财务负责人李春桦的辞职报告，李春桦因个人原因申请辞去公司副总经理、董事会秘 书、财务负责人职务，辞职后李春桦将不再担任公司其他职务，其辞职报告自送达公司董事会之日起生 效。 简历显示，秦坤，1983年10月出生，对外经济贸易大学经济学硕士学位，注册会计师，注册税务师。曾 任北京世纪地和控股有限公司财务总监，北京清新环境技术股份有限公司董事会秘书、资本运营部总经 理，四川发展国润水务投资有限公司董事。 公告显示，为保证公司董事会的日常运作及公司信息披露等工作的开展，公司于12月4日召开第四届董 事会第十七次会议，审议通过了《关于聘任副总经理、董事会秘书的议案》。同意聘任秦坤为公司副总 经理、董事会秘书。 ...

截至发稿，科源制药市值为30亿元。 每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 每经AI快讯，科源制药（SZ 301281，收盘价：27.76元）12月4日晚间发布公告称，山东科源制药股份 有限公司于近日收到公司副总经理、董事会秘书、财务负责人李春桦先生的辞职报告，李春桦先生因个 人原因申请辞去公司副总经理、董事会秘书、财务负责人职务，辞职后李春桦先生将不再担任公司其他 职务，其辞职报告自送达公司董事会之日起生效。公司同意聘任秦坤女士为公司副总经理、董事会秘 书。 （记者 张明双） 2025年1至6月份，科源制药的营业收入构成为：医药制造业占比100.0%。 ...